USE OF SAA, RSAA OR INHIBITORS OF SAA IN THE TREATMENT OF DYSREGULATED INFLAMMATIONS

摘要

The present invention describes use of recombinant serum amyloid A proteins (rSAAs) and native serum amyloid A proteins (SAAs) with their natural carrier and an inhibitor of SAA, particularly high density lipoprotein (HDL), in the treatment of a condition or disease that are characterized by dysregulated inflammation. Thereby, in case of dysregulated inflammation with an excessive inflammation, the function of rSAAs and SAAs may be inactivated by binding SAA to HDL at inducing normal temperature or graded hypothermia, leading to an increased amount of SAAs-HDL-complex in said subject in vivo, and reversely in case of dysregulated inflammation which has led to low temperatures and hypothermia (suppressed inflammation), rSAA may be administered and/or the SAA level may be increased by separating the SAAs-HDL complex, wherein said step also includes inducing gradual hyperthermia in the subject.